VACCINEX INC
NASDAQ: VCNX (Vaccinex, Inc.)
Last update: 10 hours ago1.06
0.31 (41.31%)
| Previous Close | 0.750 |
| Volume | 10,120 |
| Price / Sales | 2.62 |
| Price / Book | 7.34 |
| 52 Weeks Range |
| Operating Margin (TTM) | -1,590.14% |
| Diluted EPS (TTM) | -8.88 |
| Quarterly Revenue Growth (YOY) | 160.00% |
| Total Debt/Equity (MRQ) | 6.97% |
| Current Ratio (MRQ) | 0.500 |
| Operating Cash Flow (TTM) | -16.19 M |
| Levered Free Cash Flow (TTM) | -11.54 M |
| Return on Assets (TTM) | -376.08% |
| Return on Equity (TTM) | -759.09% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Vaccinex, Inc. | - | - |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | -1.43 |
|
Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company’s lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer’s Disease, with ongoing exploration of potential Phase 3 development in Huntington’s disease. The firm has also developed a proprietary drug discovery platform, ActivMAb. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 11.51% |
| % Held by Institutions | 45.01% |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |